17 results about "Alternative treatment" patented technology

The invention relates to the technical field of medical informatization, in particular to a remote management method and system for CRRT and nutrition state linkage and a storage medium, and the method comprises the following steps: obtaining a physical sign index through a wearable device, and obtaining a continuous renal replacement therapy CRRT metabolism index and a laboratory index; training a machine learning model by using an Internet of Things cloud platform based on the physical sign indexes, the CRRT metabolism indexes and the laboratory indexes, and constructing a multi-parameter decision model for nutrition demand prediction, CRRT machine setting and nutrition risk early warning; and adjusting a CRRT machine and nutrition supply by using the mobile terminal according to the output of the multi-parameter decision model, and carrying out early warning on nutrition risks. According to the method, real-time vital signs, CRRT clearing data and laboratory indexes are dynamically integrated through a multi-parameter decision model, and accurate quantification and dynamic matching of nutritional requirements and CRRT prescriptions are achieved.

The invention relates to methods for predicting an outcome for a prostate cancer patient. In particular the method describes a model based on the expression levels of marker genes which can be used to predict the effectiveness of androgen deprivation therapy (ADT). The method allows for treatment suggestions, particularly for those patients where ADT is predicted not to be effective, and alternative treatment may be desirable. The invention further describes kits useful for use in the described methods, as well as composition for use in treatment of prostate cancer based on a treatment outcome prediction described herein.

Various methods and compositions of treating 4-hydroxyphenylpyruvate dioxygenase-like (HPDL)-related diseases or disorders are presented herein. Also presented herein are methods of increasing CoQ10 biosynthesis, and methods of determining whether a subject will benefit from a CoQ10 or CoQ10 alternative treatment. Also presented herein are pharmaceutical compositions and dosage forms comprising 4-hydroxymandelic acid (4-HMA), and / or its metabolites. Further presented herein are compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase-like (HPDL). Further presented herein are methods of identifying and / or assessing modulators of HPDL. Yet further presented herein are example methods and systems for isotopic labelling in cells by metabolizing cells in the presence of gaseous isotopic tracer.

In some embodiments, a method may include receiving, from an electromechanical machine, a sensor, and a computing device, data associated with a user that uses the electromechanical machine to perform a treatment plan, correlating, using an artificial intelligence engine, at least two of a pain measurement, an indication of medication utilization, and a measurement of revolutions per minute to generate a unique data signature associated with a treatment gap associated with the treatment plan performed by the user. Based on the unique data signature, generating, using the artificial intelligence engine, alternative treatment plans for the user, based on a threshold compliance level associated with each of the alternative treatment plans, selecting an alternative treatment plan from the alternative treatment plans, and controlling, while the user uses the electromechanical machine and based on the alternative treatment plan, the electromechanical machine.

The application relates to the technical field of tunnel construction, in particular to a classification and grading reinforcement method for a tunnel portal, which comprises the following steps: step S1, acquiring field investigation data, and establishing a tunnel portal section topography and geology parameter model according to the field investigation data; step S2, grading tunnel portal deformation characteristics; step S3, grading tunnel portal deformation control levels; step S4, selecting a tunnel portal deformation treatment scheme according to the grading; step S5, combining different construction methods to formulate multiple alternative treatment schemes; and step S6, determining an optimal scheme based on multi-target optimization. The application has the advantages of strong applicability, high fine degree, high reliability, quantitative analysis and an engineering guiding significance of a comprehensive evaluation system.

Provided is a pharmaceutical composition for preventing or treating benign prostatic hyperplasia or alopecia, comprising lactic acid bacteria of Enterococcus genus as an active ingredient. The pharmaceutical composition of the present invention can replace the conventional therapeutic agents against treating benign prostatic hyperplasia or alopecia, such as finasteride or dutasteride. In particular, by introducing heat-killed probiotics of Enterococcus faecalis, the effect of preventing or treating benign prostatic hyperplasia or alopecia can be further enhanced.

The invention discloses a liquid management and volume monitoring system for continuous kidney replacement therapy of critical patients, which comprises a volume monitoring module, a microcirculation monitoring module, a data processing core module, an intelligent regulation and control module and a man-machine interaction module which are in two-way communication connection through a data bus, and the data processing core module is a system control center; the volume monitoring module comprises a noninvasive blood volume detection unit and an individualized infusion regulation and control unit. Through closed-loop automatic adjustment of the contact force of the probe, constant contact pressure between the probe and the skin of a patient is ensured, and imaging distortion caused by abnormal pressure is avoided; meanwhile, through three-dimensional coordinate monitoring and displacement influence coefficient quantification of patient displacement, in combination with an invalid data filtering algorithm based on a convolutional neural network, invalid data generated by interference are automatically filtered, the invalid data recognition accuracy is improved, the reliability of microcirculation monitoring data and blood volume monitoring data is greatly improved, and clinical misjudgment is avoided.

The invention relates to the technical field of medical treatment, in particular to self-adaptive accurate liquid management CRRT equipment which comprises a continuous kidney replacement therapeutic apparatus body, a heat insulation cover, a temperature control assembly, a marking assembly and an alarm assembly, the heat insulation cover is fixedly connected to the outer wall of one side of the continuous kidney replacement therapeutic apparatus body, the temperature control assembly is installed in the heat insulation cover, and the marking assembly is fixedly connected to the outer wall of the other side of the continuous kidney replacement therapeutic apparatus body. A marking assembly is installed on the outer side of the heat insulation cover, and alarm assemblies are installed on the outer walls of the two sides of the heat insulation cover. The temperature control assembly comprises a heating tank, a temperature control circulating pipe and a first motor; a temperature control assembly is adopted, temperature control treatment can be conducted on the blood circulation and purification environment, the influence of the external temperature difference is avoided, the accuracy of liquid circulation is ensured, and the using effect of the equipment is improved; and the marking assembly is adopted, and when the pressure of the equipment changes, the connection loosening position can be rapidly marked, so that medical staff can rapidly maintain the equipment, the safety of the equipment is improved, and the using effect of the equipment is improved.

The invention relates to a method for applying a medical big language model of an integrated knowledge graph to drug analysis and diagnosis support. The method comprises the steps of performing streaming analysis and entity recognition on a structured pharmaceutical database file, generating a drug record set containing standardized biomedical entity annotations, and constructing a graph structure knowledge base and a vector index base in parallel; receiving a natural language query, extracting drugs and disease entities and mapping the drugs and disease entities into standardized identifiers; synchronously retrieving the structured evidence set and the text evidence set; assembling an enhanced prompt text containing the task instruction, the verified evidence and the query according to the template; and inputting the large language model subjected to biomedical task fine tuning, and generating a binding response. By adopting the method, the problems of static stiffness, pure language model illusion and insufficient interaction of a structured knowledge base of a traditional system can be solved, reliable decision assistance is provided for replacement treatment and interaction review under the condition of drug shortage, and the drug use risk is reduced.

Bacterial infections evading the current antibiotic arsenal warrant new treatment options. The mainstay treatment for Clostridium difficile infections involves administration of the broad-spectrum antibiotic vancomycin, which also depletes the gut microbiome and its natural defenses. This leads to recurrent C. difficile infections in 20-30% of patients. Alternative treatment options are limited, triggering a perpetual cycle of relapse and recovery that may eventually lead to death. Keratinicyclin B represents a glycopeptide antibiotic chemotype with a mechanism of action that is selective for Clostridia. When combined, vancomycin (or other glycopeptide antibiotic) and keratinicyclin B interact synergistically to inhibit the growth of C. difficile at concentrations far lower than their respective minimal inhibitory concentrations. Such a combination therapy could allow for targeted colonization clearance at low antibiotic doses, thereby minimizing toxicity and reducing the likelihood of relapse.

The present invention relates to a rheumatoid arthritis treatment method comprising a step of irradiating an affected area of a patient that has rheumatoid arthritis with low-dose radiation, wherein the inflammation of rheumatoid arthritis is alleviated by inducing apoptosis of immune cells, and an alternative treatment method, instead of surgery, can be provided to patients with DMARD resistance.

1. The name of the design product: waste liquid collection adapter pipe. 2. The use of the design product: for the matching medical consumables of continuous renal replacement therapy equipment. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

The invention discloses a continuous blood purification device and method, and belongs to the technical field of blood purification equipment.The continuous blood purification device comprises a continuous kidney replacement therapy machine body, a PLC is installed on the top face of the machine body, and an input liquid pipe is connected to one input end of a dialyzer body through a blood pump; the middle of the bottom end of the mixing box is fixedly provided with a mixed medicine outlet pipe, the mixed medicine outlet pipe is communicated with an input port in the top of the dialyzer body, the mixing box is internally provided with an ultrasonic stirrer, the top of the mixing box is rotatably provided with a medicine feeding assembly, and the medicine feeding assembly comprises a medicine storage cylinder and a liquid storage cylinder which are symmetrically arranged; discharging pipes are fixed to the bottoms of the medicine storage cylinders and the bottoms of the liquid storage cylinders, metering pumps are installed on the discharging pipes, the number of the medicine storage cylinders is at least two, the number of the liquid storage cylinders is at least two, and the device has the technical effects of being accurate in metering, efficient in mixing, continuous in operation and safe in treatment.

This invention relates to the field of healthcare information technology, and in particular to a method and apparatus for generating personalized treatment plans for refractory wounds at high altitudes. The method includes: collecting basic information, wound information, high-altitude environment information, and drug metabolism data of historical patients; correcting the basal drug absorption rate and basal drug metabolism rate based on the high-altitude environment information and basic information to obtain high-altitude corrected drug absorption rate and high-altitude corrected drug metabolism rate; determining alternative treatment plans for historical patients based on their wound information, basic information, high-altitude corrected drug absorption rate, and high-altitude corrected drug metabolism rate; predicting the wound healing index, adverse drug reaction risk, and treatment adherence of historical patients based on the alternative treatment plans; adjusting the alternative treatment plans based on a reward function, and evaluating the suitability score of each treatment plan to obtain the treatment plan with the highest suitability score, thereby providing the optimal treatment plan for the target patient.

To provide alternative treatments for subjects suffering from diseases, disorders, and conditions related to the oxalate pathway. [Solution] The present invention relates to a double-stranded ribonucleic acid (dsRNA) composition that targets the LDHA gene, a method for inhibiting LDHA expression, a method for inhibiting LDHA and HAO1 using such a dsRNA composition, and a method for treating subjects who may benefit from reduced LDHA expression, for example, subjects suffering from diseases, disorders or conditions related to the oxalate pathway.

An electronic data interface overlay for modifying existing formulary data is provided along with systems and methods for the same. The overlay comprises member-specific clinical data and causes automatic generation of code(s) indicating coverage denial upon querying of treatments of the existing formulary data associated with certain of the member-specific clinical data, such as pharmacogenetic (“PGx”) test results, of the data interface overlay. The formulary data includes alternative treatments which may be suggested and approved upon denial based on PGx test results. An electronic health record is automatically updated with the alternative treatment.

The application provides an integrated fixing frame for a continuous kidney replacement therapy pipeline, comprising: a fixing clamp; a mounting frame sleeved on the fixing clamp; a pipe clamp assembly fixedly installed on the mounting frame and used for mounting a treatment instrument; and a locking mechanism comprising an adjusting rod, an adjusting piece and a pressing ring, wherein the adjusting rod is installed on the mounting frame, the pressing ring is slidably installed on the inner side of the mounting frame, the adjusting rod can be rotated clockwise and counterclockwise, the pressing ring can be moved up and down by the adjusting piece, the pressing ring can exert pressure on the hinge of the fixing clamp when moving downward, the fixing clamp is provided with a slot, and the adjusting rod can be inserted into the slot when moving downward. The technical problem that the treatment pipeline may be subjected to continuous or instantaneous external force due to changes in the patient's body position, pulling by medical care operation or accidental hooking, and the fixing frame is difficult to resist such pulling only by the simple engagement of the elastic clamp and the mounting rod, and the fixing frame is prone to sliding, displacement and even falling off from the mounting rod as a whole can be solved.